Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Intellia Thera CS(NTLA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.55
Day High13.54
Open:12.73
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Intellia Thera CS

Select a category then submit the form to load news
GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Intellia Therapeutics (NTLA) Gets a Hold from Wedbush
Tipranks
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA)
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (DNLI), Eton Pharmaceuticals (ETON) and Intellia Therapeutics (NTLA)
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Tipranks
Intellia Resumes Key Trial and Expands ATM Program
Newswire.ca
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Tipranks
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)
GlobeNewswire
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Tipranks
H.C. Wainwright Remains a Buy on Intellia Therapeutics (NTLA)
GlobeNewswire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Tipranks
Intellia Therapeutics Eyes 2026 Pivotal CRISPR Milestone
Tipranks
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Intellia Therapeutics (NTLA) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Tipranks
Bank of America Securities Sticks to Its Hold Rating for Intellia Therapeutics (NTLA)
Tipranks
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tango Therapeutics (TNGX)
Motley Fool
Intellia (NTLA) Q4 2025 Earnings Call Transcript
GlobeNewswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
GlobeNewswire
Intellia Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Motley Fool
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?
GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tipranks
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE)
Tipranks
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Cardiff Oncology (CRDF)
Tipranks
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)
Tipranks
FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial
GlobeNewswire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Profile

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.